Tectonic Therapeutic Stifel 2026 Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right, we can get started so we can make sure to get through all of our questions. But great to be here with Tectonic Therapeutic. We have CEO Alise Reicin. Great to have you here.
Thanks for joining. Thanks for the invitation.
Of course. Really interesting time for you guys. Maybe we can just start with a kind of like a brief overview of kind of like what's coming and kind of how you're framing it for folks.
We have a catalyst-rich 2027.
It'll start with our TX45, our lead program.
We'll have phase II data by end of January. We will not be at JP Morgan, so you can expect it sometime between JP Morgan and hopefully end of January. So that'll be data from our phase II study.
in group two pulmonary hypertension and HFpEF. We are actively enrolling our PH-ILD study with TX45.
We expect interim data from that study, which is a single-arm study of about 20 to 25 patients, second half of 2027.
We are just about, between now and the end of the year, we will start our phase I-B study with our APJ antagonist, TX2100, in patients with HHT who require hematologic support.
We should have interim data from that study, so our second program in hereditary hemorrhagic telangiectasia, by the end of 2027. In early 2027, we will start our phase II study in moderate to severe, in patients with HHT with moderate to severe epistaxis.
Mm-hmm. Yeah, very busy time. Maybe we can just start with HHT, since you had some data recently. I think there is a lot of investor interest in HHT and sort of an appreciation that it could be a big rare disease market, but there is obviously a lot of companies and different mechanisms. So, maybe just kind of like set the stage on your mechanism, kind of this sort of like thesis behind it, and then some of the initial healthy volunteer data you have.
So, why don't I start with HHT, because not all investors know HHT yet. HHT is the second most common genetic bleeding disorder. It impacts about 75,000 to 80,000 patients in the U.S. alone, over 1 million worldwide, and it is basically a disease of dysregulated angiogenesis. It is mutations in the BMP9/ALK pathway. Anti-VEGF inhibitors, anti-angiogenic agents have been shown to work in preclinical models of the disease, and that has translated to the clinic. TX2100 is an antagonist antibody to APJ- which is an anti-angiogenic agent.
But it's a more specific and selective approach to angiogenesis. So what we hope is to have the efficacy, or maybe even better efficacy than the currently used therapies, none of which are approved.
because we'll have a better safety profile, and then as I said, efficacy as good as and maybe even better than those.
Yeah. Makes sense. And obviously it sounds like safety is the core part of that thesis and.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
1 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
